CancerDrs

Colorectal Cancer clinical trials in California

114 actively recruiting colorectal cancer trials at 102 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Deer Valley Medical Center — Antioch, California
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • PCR Oncology — Arroyo Grande, California
  • Sutter Auburn Faith Hospital — Auburn, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in California:
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
  • Mercy Cancer Center - Carmichael — Carmichael, California
  • Mercy San Juan Medical Center — Carmichael, California
  • Mercy Cancer Center - Elk Grove — Elk Grove, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • Cedars-Sinai Medical Center — Los Angeles, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in California:
  • Los Angeles Cancer Network - Anaheim — Anaheim, California
  • Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim, California
  • Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California
  • Kaiser Permanente Bellflower Medical Offices — Bellflower, California
  • Kaiser Permanente Fontana Medical Center — Fontana, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in California:
  • Memorial Care Orange Coast Medical Center — Fountain Valley, California
  • Providence Medical Foundation — Fullerton, California
  • Cancer & Blood Research Center — Los Alamitos, California
  • University of California Los Angeles Health — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…

Sponsor: Amgen
NCT ID: NCT06252649
Sites in California:
  • Providence Saint Jude Medical Center — Fullerton, California
  • City of Hope National Medical Center — Long Beach, California
  • Cancer and Blood Research Center, LLC — Los Alamitos, California
  • California Research Institute — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Sponsor: Surgimab
NCT ID: NCT03659448
Sites in California:
  • City of Hope National Medical Center — Duarte, California
  • Moores Cancer Center - UCSD Health — La Jolla, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California:
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • Sansum Clinic — Santa Barbara, California
  • Providence Medical Foundation — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in California:
  • University of California, Los Angeles (UCLA) — Los Angeles, California
  • Stanford Cancer Institute, Stanford University — Palo Alto, California
  • University of California San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California
  • Sarcoma Oncology Center — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in California:
  • The Oncology Institute of Hope and Innovation — Cerritos, California
  • Ellison Medical Institute — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • University of California Los Angeles — Los Angeles, California
  • University of California Irvine — Orange, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…

Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in California:
  • Investigative Site — Los Angeles, California
  • Investigative Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…

Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in California:
  • Central Recruiting Site — Fair Oaks, California
  • Central Recruiting Site — Fountain Valley, California
  • Central Recruiting Site — Los Angeles, California
  • Central Recruiting Site — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…

Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in California:
  • City of Hope Medical Center — Durate, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • HOAG Memorial Hospital Presbyterian — Newport Beach, California
  • Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
  • Stanford Health Care — Stanford, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in California:
  • UCSD — La Jolla, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • Sharp Healthcare — San Diego, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…

Sponsor: AbbVie
NCT ID: NCT07023289
Sites in California:
  • Providence Medical Foundation - Fullerton /ID# 274207 — Fullerton, California
  • USC Norris Comprehensive Cancer Center /ID# 274550 — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California:
  • Children's Hospital Los Angeles — Los Angeles, California
  • Children's Hospital of Orange County — Orange, California
  • Lucile Packard Children's Hospital Stanford University — Palo Alto, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in California:
  • The Angeles clinic - A cedars SINAI AFFILIATE — Los Angeles, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • University of California, San Francisco (UCSF) — San Francisco, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California:
  • Los Angeles Cancer Network — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • Pih Health Hematology Medical Oncology — Whittier, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…

Sponsor: AbbVie
NCT ID: NCT06820463
Sites in California:
  • City of Hope National Medical Center /ID# 270255 — Duarte, California
  • UCLA - Santa Monica /ID# 270621 — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in California:
  • UCLA ( Site 0317) — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in California:
  • The Angeles Clinic and Research Institute — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Sponsor: NGM Biopharmaceuticals, Inc
NCT ID: NCT07033026
Sites in California:
  • NGM Clinical Study Site — Los Angeles, California
  • NGM Clinical Study Site — Los Angeles, California
  • NGM Clinical Study Site — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in California:
  • UCSD Moores Cancer Center — La Jolla, California
  • UCLA Medical Center — Los Angeles, California
  • Stanford University — Stanford, California
View on ClinicalTrials.gov →

Showing 25 of 114 trials with sites in California. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07